502 related articles for article (PubMed ID: 36697706)
1. Immunology and immunotherapy of cholangiocarcinoma.
Greten TF; Schwabe R; Bardeesy N; Ma L; Goyal L; Kelley RK; Wang XW
Nat Rev Gastroenterol Hepatol; 2023 Jun; 20(6):349-365. PubMed ID: 36697706
[TBL] [Abstract][Full Text] [Related]
2. Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and Therapy.
Kabbara KW; Cannon T; Winer A; Wadlow RC
Oncology (Williston Park); 2022 Aug; 36(8):492-498. PubMed ID: 36001788
[TBL] [Abstract][Full Text] [Related]
3. Cholangiocarcinoma - novel biological insights and therapeutic strategies.
Ilyas SI; Affo S; Goyal L; Lamarca A; Sapisochin G; Yang JD; Gores GJ
Nat Rev Clin Oncol; 2023 Jul; 20(7):470-486. PubMed ID: 37188899
[TBL] [Abstract][Full Text] [Related]
4. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
[TBL] [Abstract][Full Text] [Related]
5. [Recent progress in molecular targeted therapies for intrahepatic cholangiocarcinoma].
Xie ZH; Li J; Xia Y; Shen F
Zhonghua Wai Ke Za Zhi; 2020 Apr; 58(4):289-294. PubMed ID: 32241059
[TBL] [Abstract][Full Text] [Related]
6. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in cholangiocarcinoma.
Al-Rajabi R; Sun W
Curr Opin Gastroenterol; 2021 Mar; 37(2):105-111. PubMed ID: 33507028
[TBL] [Abstract][Full Text] [Related]
8. Future directions in the treatment of cholangiocarcinoma.
Zhu AX
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Biliary Tract Cancers: Where Are We?
Kalyan A; Khosla H; Kim RD
Curr Oncol Rep; 2022 Dec; 24(12):1821-1828. PubMed ID: 36192517
[TBL] [Abstract][Full Text] [Related]
10. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.
Cao H; Huang T; Dai M; Kong X; Liu H; Zheng Z; Sun G; Sun G; Rong D; Jin Z; Tang W; Xia Y
Int J Biol Sci; 2022; 18(14):5369-5390. PubMed ID: 36147461
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy and targeted therapy for cholangiocarcinoma: Artificial intelligence research in imaging.
Liu J; Shu J
Crit Rev Oncol Hematol; 2024 Feb; 194():104235. PubMed ID: 38220125
[TBL] [Abstract][Full Text] [Related]
12. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
Zhang Q; Lou Y; Bai XL; Liang TB
World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
[TBL] [Abstract][Full Text] [Related]
13. The state of therapy modalities in clinic for biliary tract cancer.
Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
[TBL] [Abstract][Full Text] [Related]
14. Case Report: A novel mixture of dose-fractioned radiation and immunotherapy for treatment of cholangiocarcinoma.
Wang N; Wang L; Huang A; Han J; Cao T; Mei X; Yao J; Xiao Y; Ma H
Front Immunol; 2023; 14():1273962. PubMed ID: 38162668
[TBL] [Abstract][Full Text] [Related]
15. Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future.
Rizzo A; Ricci AD; Cusmai A; Acquafredda S; De Palma G; Brandi G; Palmiotti G
Curr Oncol; 2022 Jan; 29(2):551-564. PubMed ID: 35200550
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapies for intrahepatic cholangiocarcinoma.
Kelley RK; Bridgewater J; Gores GJ; Zhu AX
J Hepatol; 2020 Feb; 72(2):353-363. PubMed ID: 31954497
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers.
Chen R; Zheng D; Li Q; Xu S; Ye C; Jiang Q; Yan F; Jia Y; Zhang X; Ruan J
Cancer Lett; 2022 Oct; 546():215853. PubMed ID: 35921970
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors and combinations with other agents in cholangiocarcinoma.
Skouteris N; Papageorgiou G; Fioretzaki R; Schizas D; Kykalos S; Tolia M; Charalampakis N
Immunotherapy; 2023 May; 15(7):487-502. PubMed ID: 36876442
[TBL] [Abstract][Full Text] [Related]
19. Cholangiocarcinoma.
Krasinskas AM
Surg Pathol Clin; 2018 Jun; 11(2):403-429. PubMed ID: 29751883
[TBL] [Abstract][Full Text] [Related]
20. Molecular therapeutic targets for cholangiocarcinoma: Present challenges and future possibilities.
Høgdall D; O'Rourke CJ; Andersen JB
Adv Cancer Res; 2022; 156():343-366. PubMed ID: 35961705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]